Review

hy 100113 (MedChemExpress)

Name: hy 100113
Brand: MedChemExpress
Rating: 94 (5 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress hy 100113
Hy 100113, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy 100113/product/MedChemExpress
Average 94 stars, based on 5 article reviews

hy 100113 - by Bioz Stars, 2026-02

94/100 stars

Images

Image Search Results

AT2R activation improved neurological recovery after TBI. (A) Workflow detailing the timeline for drug interventions and behavioral tests. (B) mNSS after TBI. (C, D) Latency to fall on the rotarod test after TBI. (E) Representative track sheets from the open-field test probe trial. (F, G) OFT results: Time spent in the central zone (F) and frequency of entries into the central zone (G) . (H) Schematic diagram representation of the NOR test. The schematic diagram was created with BioRender.com. A1 and A2 represent old objects, while B represents the novel object. (I) Representative heatmaps from the NOR test probe trial. (J) NOR index for each group. (K) Schematic diagram of the MWM test. The schematic diagram was created with BioRender.com. (L) Representative swimming traces and heatmaps from the MWM test. (M) Learning curve during the training phase of the MWM test. (N, O) MWM probe trial results: number of platform crossings (N) and time spent in the target quadrant (O) for each group. All data are presented as mean ± SD (n = 10 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Journal: Theranostics

Article Title: Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury

doi: 10.7150/thno.117743

Figure Lengend Snippet: AT2R activation improved neurological recovery after TBI. (A) Workflow detailing the timeline for drug interventions and behavioral tests. (B) mNSS after TBI. (C, D) Latency to fall on the rotarod test after TBI. (E) Representative track sheets from the open-field test probe trial. (F, G) OFT results: Time spent in the central zone (F) and frequency of entries into the central zone (G) . (H) Schematic diagram representation of the NOR test. The schematic diagram was created with BioRender.com. A1 and A2 represent old objects, while B represents the novel object. (I) Representative heatmaps from the NOR test probe trial. (J) NOR index for each group. (K) Schematic diagram of the MWM test. The schematic diagram was created with BioRender.com. (L) Representative swimming traces and heatmaps from the MWM test. (M) Learning curve during the training phase of the MWM test. (N, O) MWM probe trial results: number of platform crossings (N) and time spent in the target quadrant (O) for each group. All data are presented as mean ± SD (n = 10 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Article Snippet: C21 (HY-100113, MedChemExpress), a highly specific AT2R receptor agonist, was dissolved in phosphate buffered saline (PBS).

Techniques: Activation Assay

AT2R activation enhanced glymphatic influx in acute TBI mice. (A, B) Experimental workflow (A) and schematic diagram (B) of transcranial NIR-II imaging to assess glymphatic influx. The schematic diagram was created with BioRender.com. (C, D) High-contrast transcranial imaging (C) and quantification of fluorescence intensity (D) for BSA@IR-780. Scale bar = 4 mm. (E, F) Representative images of BSA@IR-780 influx into the PVS (E) and corresponding fluorescence quantification (F). Scale bar = 2 mm. (G) Representative images of BSA@IR-780 distribution on dorsal and ventral brain surfaces. Scale bar = 4 mm. (H, I) Quantified fluorescence intensity on the dorsal (H) and ventral (I) surfaces. (J) Representative images of coronal slices at the indicated distances from bregma. Scale bar = 2 mm. (K, L) Quantified fluorescence intensity across all slices (K) and per slice (L). (M, N) Workflow (M) and schematic diagram (N) for non-invasive NIR-II imaging of superficial CLNs drainage in mice. The schematic diagram was created with BioRender.com. (O, P) Representative images (O) and fluorescence quantification (P) of superficial CLNs drainage. Scale bar = 4 mm. All data are presented as mean ± SD (n = 6 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Journal: Theranostics

Article Title: Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury

doi: 10.7150/thno.117743

Figure Lengend Snippet: AT2R activation enhanced glymphatic influx in acute TBI mice. (A, B) Experimental workflow (A) and schematic diagram (B) of transcranial NIR-II imaging to assess glymphatic influx. The schematic diagram was created with BioRender.com. (C, D) High-contrast transcranial imaging (C) and quantification of fluorescence intensity (D) for BSA@IR-780. Scale bar = 4 mm. (E, F) Representative images of BSA@IR-780 influx into the PVS (E) and corresponding fluorescence quantification (F). Scale bar = 2 mm. (G) Representative images of BSA@IR-780 distribution on dorsal and ventral brain surfaces. Scale bar = 4 mm. (H, I) Quantified fluorescence intensity on the dorsal (H) and ventral (I) surfaces. (J) Representative images of coronal slices at the indicated distances from bregma. Scale bar = 2 mm. (K, L) Quantified fluorescence intensity across all slices (K) and per slice (L). (M, N) Workflow (M) and schematic diagram (N) for non-invasive NIR-II imaging of superficial CLNs drainage in mice. The schematic diagram was created with BioRender.com. (O, P) Representative images (O) and fluorescence quantification (P) of superficial CLNs drainage. Scale bar = 4 mm. All data are presented as mean ± SD (n = 6 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Article Snippet: C21 (HY-100113, MedChemExpress), a highly specific AT2R receptor agonist, was dissolved in phosphate buffered saline (PBS).

Techniques: Activation Assay, Imaging, Fluorescence

AT2R activation promoted glymphatic clearance in acute TBI mice. (A, B) Experimental workflow (A) and schematic diagram (B) for transcranial NIR-II imaging of parenchymal IR-808Ac clearance. The schematic diagram was created with BioRender.com. (C-E) High-contrast transcranial NIR-II imaging (C) and fluorescence intensity analysis of IR-808Ac (D, E). Scale bar = 4 mm. (F) Representative images of IR-808Ac distribution on dorsal and ventral brain surfaces. Scale bar = 4 mm. (G) Representative images of coronal slices at the indicated distances from bregma. Scale bar = 2 mm. (H, I) Quantified fluorescence intensity on the dorsal (H) and ventral (I) surfaces. (J, K) Quantified fluorescence intensity across all slices (J) and per slice (K). (L, M) Workflow (L) and schematic diagram (M) illustrating IR-808 delivery and detection in the femoral vein. The schematic diagram was created with BioRender.com. (N, O) Representative femoral vein images (N) and fluorescence quantification (O) of IR-808. Scale bar = 4 mm. All data are presented as mean ± SD (n = 6 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Journal: Theranostics

Article Title: Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury

doi: 10.7150/thno.117743

Figure Lengend Snippet: AT2R activation promoted glymphatic clearance in acute TBI mice. (A, B) Experimental workflow (A) and schematic diagram (B) for transcranial NIR-II imaging of parenchymal IR-808Ac clearance. The schematic diagram was created with BioRender.com. (C-E) High-contrast transcranial NIR-II imaging (C) and fluorescence intensity analysis of IR-808Ac (D, E). Scale bar = 4 mm. (F) Representative images of IR-808Ac distribution on dorsal and ventral brain surfaces. Scale bar = 4 mm. (G) Representative images of coronal slices at the indicated distances from bregma. Scale bar = 2 mm. (H, I) Quantified fluorescence intensity on the dorsal (H) and ventral (I) surfaces. (J, K) Quantified fluorescence intensity across all slices (J) and per slice (K). (L, M) Workflow (L) and schematic diagram (M) illustrating IR-808 delivery and detection in the femoral vein. The schematic diagram was created with BioRender.com. (N, O) Representative femoral vein images (N) and fluorescence quantification (O) of IR-808. Scale bar = 4 mm. All data are presented as mean ± SD (n = 6 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Article Snippet: C21 (HY-100113, MedChemExpress), a highly specific AT2R receptor agonist, was dissolved in phosphate buffered saline (PBS).

Techniques: Activation Assay, Imaging, Fluorescence

AT2R activation inhibited neuroinflammatory responses in acute TBI mice. (A) Flowchart of the RNA-seq analysis. (B) Venn diagram illustrating genetic variations. (C) Statistically up-regulated and down-regulated DEGs. (D) Cluster map of the DEGs among TBI+C21 group and TBI group. (E) Down-regulated biological process of gene ontology function enrichment of the DEGs in the TBI+C21 group compared with the TBI group. n = 5 per group.

Journal: Theranostics

Article Title: Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury

doi: 10.7150/thno.117743

Figure Lengend Snippet: AT2R activation inhibited neuroinflammatory responses in acute TBI mice. (A) Flowchart of the RNA-seq analysis. (B) Venn diagram illustrating genetic variations. (C) Statistically up-regulated and down-regulated DEGs. (D) Cluster map of the DEGs among TBI+C21 group and TBI group. (E) Down-regulated biological process of gene ontology function enrichment of the DEGs in the TBI+C21 group compared with the TBI group. n = 5 per group.

Article Snippet: C21 (HY-100113, MedChemExpress), a highly specific AT2R receptor agonist, was dissolved in phosphate buffered saline (PBS).

Techniques: Activation Assay, RNA Sequencing

AT2R activation suppressed β-amyloid and phosphorylated tau accumulation in chronic TBI mice. (A, B) Representative transcranial NIR-II images (A) and quantified fluorescence intensity (B) of BSA@IR-780. Scale bar = 4 mm. (C) Representative images of BSA@IR-780 distribution on dorsal and ventral brain surfaces, as well as in coronal slices. Scale bars: 4 mm (surfaces), 2 mm (slices). (D-F) Quantified fluorescence intensity on dorsal (D) and ventral (E) surfaces, and across coronal slices (F). (G, H) Representative images (G) and quantification (H) of FITC-labeled β-amyloid (1-42) in brain parenchyma. Scale bar = 400 μm. (I-M) Western blots (I) and quantification of tau markers in perilesional cortex: pTauThr205 (J), pTauSer396 (K), pTauSer404 (L), and Tau5 (M). All data are presented as mean ± SD (n = 6 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Journal: Theranostics

Article Title: Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury

doi: 10.7150/thno.117743

Figure Lengend Snippet: AT2R activation suppressed β-amyloid and phosphorylated tau accumulation in chronic TBI mice. (A, B) Representative transcranial NIR-II images (A) and quantified fluorescence intensity (B) of BSA@IR-780. Scale bar = 4 mm. (C) Representative images of BSA@IR-780 distribution on dorsal and ventral brain surfaces, as well as in coronal slices. Scale bars: 4 mm (surfaces), 2 mm (slices). (D-F) Quantified fluorescence intensity on dorsal (D) and ventral (E) surfaces, and across coronal slices (F). (G, H) Representative images (G) and quantification (H) of FITC-labeled β-amyloid (1-42) in brain parenchyma. Scale bar = 400 μm. (I-M) Western blots (I) and quantification of tau markers in perilesional cortex: pTauThr205 (J), pTauSer396 (K), pTauSer404 (L), and Tau5 (M). All data are presented as mean ± SD (n = 6 per group). Statistical significance: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus sham group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus TBI+C21 group.

Article Snippet: C21 (HY-100113, MedChemExpress), a highly specific AT2R receptor agonist, was dissolved in phosphate buffered saline (PBS).

Techniques: Activation Assay, Fluorescence, Labeling, Western Blot

TBI impairs glymphatic transport and is counteracted by AT2R activation. Under physiological conditions, CSF flows from the subarachnoid space into the brain parenchyma through periarterial spaces, exchanges solutes with ISF, and ultimately drains via perivenous pathways (left panel). However, TBI induces structural damage to the glymphatic system, impairing glymphatic influx and clearance. Mechanistically, post-TBI glymphatic dysfunction arises primarily from reactive astrogliosis-mediated perivascular structural remodeling and loss of AQP4 polarization at astrocytic end-feet (right panel). Critically, C21-mediated AT2R activation reverses these pathological changes, restoring glymphatic transport post-TBI. Furthermore, AT2R activation suppresses neuroinflammatory responses, reduces neurotoxic protein accumulation, and improves neurological recovery.

Journal: Theranostics

Article Title: Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury

doi: 10.7150/thno.117743

Figure Lengend Snippet: TBI impairs glymphatic transport and is counteracted by AT2R activation. Under physiological conditions, CSF flows from the subarachnoid space into the brain parenchyma through periarterial spaces, exchanges solutes with ISF, and ultimately drains via perivenous pathways (left panel). However, TBI induces structural damage to the glymphatic system, impairing glymphatic influx and clearance. Mechanistically, post-TBI glymphatic dysfunction arises primarily from reactive astrogliosis-mediated perivascular structural remodeling and loss of AQP4 polarization at astrocytic end-feet (right panel). Critically, C21-mediated AT2R activation reverses these pathological changes, restoring glymphatic transport post-TBI. Furthermore, AT2R activation suppresses neuroinflammatory responses, reduces neurotoxic protein accumulation, and improves neurological recovery.

Article Snippet: C21 (HY-100113, MedChemExpress), a highly specific AT2R receptor agonist, was dissolved in phosphate buffered saline (PBS).

Techniques: Activation Assay

Review

Structured Review

Images

Similar Products

Image Search Results